Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies

Background: PRO1160 is a novel antibody-drug conjugate (ADC) directed to CD70, an antigen mediating immuno-suppression that is overexpressed in multiple solid tumors and hematologic malignancies, with limited distribution in normal tissues. PRO1160 comprises (1) a human monoclonal antibody specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonasch, Eric, Call, Justin, Kambhampati, Swetha, Caimi, Paolo, Curti, Brendan, Diefenbach, Catherine, Heath, Elisabeth, Park, Steven, Kornblum, Noah, Li, Weidong, Reimers, Melissa, Spurgeon, Stephen, Vaishampayan, Ulka, Ye, Dingwei, Zhang, Li, Zhao, Weili, Chen, Zhu, Hunder, Naomi, Ma, Sharon, Song, Eric, Garmezy, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Trials in Progress Abstract Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445573/
http://dx.doi.org/10.1093/oncolo/oyad216.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445573/
http://dx.doi.org/10.1093/oncolo/oyad216.024

Ejemplares similares